Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Chief Commercial Officer | September 01, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.77 · Expires 2036-08-31 | Direct | 1,001,738 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 1,001,738 · Balance 1,001,738 F1: 25% of the shares subject to the option vest on August 17, 2027, and the remaining shares will vest monthly thereafter over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on August 17, 2027, and the remaining shares will vest monthly thereafter over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 2, 2026 21:27 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock Option (right to buy) · Derivative | 1,001,738 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0002149973-26-000004 · form4-09022026_090920.xml · derivative · entry 1 Smith Margaret Ekins · CIK 0002149973 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,001,738 Underlying: Common Stock · 1,001,738 shares Expires 2036-08-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on August 17, 2027, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.